6,584 Shares in Danaher Corporation $DHR Purchased by Walser Wealth Management Company A Ltd Liability Co

Key Points

• Walser Wealth Management acquired 6,584 Danaher shares worth approximately $1.46 million in the third quarter. Institutional investors and hedge funds collectively own 79.05% of Danaher’s outstanding stock.
• Danaher recently exceeded quarterly expectations, reporting $1.94 in EPS and $6.26 billion in revenue, up 5.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $235.41.
• Danaher and NVIDIA announced an AI collaboration focused on autonomous science and drug discovery, while Danaher plans to launch its first commercial-scale AI-powered autonomous laboratory in early 2027.

Walser Wealth Management Company A Ltd Liability Co bought a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,584 shares of the conglomerate's stock, valued at approximately $1,459,000.

Several other hedge funds also recently bought and sold shares of the company. V Square Quantitative Management LLC lifted its holdings in Danaher by 6.9% during the third quarter. V Square Quantitative Management LLC now owns 13,696 shares of the conglomerate's stock worth $3,034,000 after acquiring an additional 884 shares in the last quarter. YANKCOM Partnership increased its holdings in shares of Danaher by 7.1% in the third quarter. YANKCOM Partnership now owns 1,893 shares of the conglomerate's stock worth $419,000 after acquiring an additional 125 shares in the last quarter. Cohen Klingenstein LLC increased its holdings in shares of Danaher by 227.1% in the third quarter. Cohen Klingenstein LLC now owns 31,400 shares of the conglomerate's stock worth $6,957,000 after acquiring an additional 21,800 shares in the last quarter. AdvisorNet Financial Inc increased its holdings in shares of Danaher by 1,832.9% in the third quarter. AdvisorNet Financial Inc now owns 12,970 shares of the conglomerate's stock worth $2,874,000 after acquiring an additional 12,299 shares in the last quarter. Finally, Barlow Wealth Partners LLC acquired a new stake in shares of Danaher during the third quarter worth about $580,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Stock Performance

Shares of DHR opened at $231.52 on Friday. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The firm has a fifty day simple moving average of $213.55 and a 200 day simple moving average of $195.74. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business earned $0.77 EPS. The company's revenue was up 5.5% compared to the same quarter last year. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's payout ratio is currently 28.42%.

Analyst Upgrades and Downgrades

DHR has been the subject of several research analyst reports. Stifel Nicolaus decreased their price objective on Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They set a "buy" rating and a $250.00 target price for the company. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a report on Monday, October 5th. Barclays lifted their price target on shares of Danaher from $230.00 to $255.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Finally, TD Cowen lifted their price target on shares of Danaher from $236.00 to $255.00 and gave the company a "buy" rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $235.41.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.